← Back to Clinical Trials
Recruiting NCT04210284

NCT04210284 Oral Nutritional Optimization in Total Joint Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04210284
Status Recruiting
Phase
Sponsor NYU Langone Health
Condition Osteoarthritis
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2021-07-06
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 55 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Ensure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2021-07-06 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to determine the effect on hematological markers of nutritional intervention on nutritionally deficient patients following total joint replacement surgery.

Eligibility Criteria

Inclusion Criteria: 1. Patient are current candidates for elective primary total hip and total knee arthroplasty 2. Patients ≥55 years of age but ≤ 95 3. Patients who meet at least one of the following three laboratory criteria for malnutrition: TSerum Albumin: ≤3.5 mg/dl Pre-Albumin: \<15 mg/dl Transferrin: \<200 mg/dl Exclusion Criteria: 1. Previous history of septic arthritis 2. Allergy to oral supplementation 3. Inability to consume oral supplementation 4. Protein malabsorption syndromes 5. Eating disorders 6. End stage renal and hepatic disease 7. Revision surgery, non-elective surgery, hemiarthroplasty, and unicompartmental knee arthroplasty

Contact & Investigator

Central Contact

Daniel Waren

✉ Daniel.waren@nyulangone.org

📞 212-598-6245

Principal Investigator

Ran Schwarzkopf

PRINCIPAL INVESTIGATOR

NYU Langone

Frequently Asked Questions

Who can join the NCT04210284 clinical trial?

This trial is open to participants of all sexes, aged 55 Years or older, studying Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04210284 currently recruiting?

Yes, NCT04210284 is actively recruiting participants. Contact the research team at Daniel.waren@nyulangone.org for enrollment information.

Where is the NCT04210284 trial being conducted?

This trial is being conducted at New York, United States, Philadelphia, United States.

Who is sponsoring the NCT04210284 clinical trial?

NCT04210284 is sponsored by NYU Langone Health. The principal investigator is Ran Schwarzkopf at NYU Langone. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology